Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

Neu­ro­science biotech Cerev­el Ther­a­peu­tics said da­ta read­outs for sev­er­al clin­i­cal tri­als will come lat­er than orig­i­nal­ly ex­pect­ed, and al­so dis­closed the up­com­ing de­par­ture of its pres­i­dent, Abra­ham Ceesay.

The af­fect­ed tri­als in­clude a Phase II in fo­cal epilep­sy for dari­ga­bat, three Phase III tri­als for tava­padon in Parkin­son’s and a Phase IIa of CVL-871 in de­men­tia-re­lat­ed ap­a­thy. The epilep­sy tri­al will read out some­time af­ter 2023, the com­pa­ny said. Da­ta had been ex­pect­ed in mid-2023. An­oth­er Phase II for dari­ga­bat will start next quar­ter in pan­ic dis­or­der.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER